Farminpex’s Post

New clinical guidelines from the American Association for the Study of Liver Diseases (AASLD) on staging liver fibrosis using imaging techniques. 🔑 The AASLD identifies VCTE, SWE and MRE as the only imaging techniques suitable for assessing fibrosis noninvasively 🔑 Still work to do in standardizing these exams for pediatric populations 🔑 MRE was the most accurate for F2 and F3 assessment, particularly in MASLD/MASH populations https://lnkd.in/g5XDJZUi

Be a research trailblazer — it’s PFF Registry Recruitment Week! Join others affected by PF and ILD who are already participating in the PFF Community Registry. Complete easy, online surveys to make a difference in the future of PF research. Get started now at bit.ly/joinpffregistry! Who can join? 🔹 Patients living with PF and ILD 🔹 Lung transplant recipients who have had PF or ILD 🔹 Caregivers and biological family members of patients with PF or ILD, including those who have passed away The more people who join, the closer we move to new research, better treatments, and ultimately a cure.

📢 Calling all clinicians and hemophilia specialists! Dive into the latest Journal of Thrombosis and Haemostasis (JTH) article: "Deconstructing the ISTH Hemophilia Guidelines for the Clinician." This must-read piece breaks down the ISTH recommendations to provide a clear, actionable roadmap for managing hemophilia patients of all ages. Read more here: https://lnkd.in/gd4MkerC 

💊 Paper to get more insights about Parkinson's disease and related disorders. 🖇 Save it to read.

The Boston University CTE Center is pushing the boundaries of neurodegenerative research, led by renowned experts Dr. Ann McKee, Dr. Thor Stein, and Dr. Michael L. Alosco at the Boston University School of Medicine. Their groundbreaking work is shifting the paradigm for diagnosing chronic traumatic encephalopathy (CTE), a condition linked to memory loss, confusion, and aggression, which currently can only be confirmed postmortem. Through the Bank CTE study, Boston University researchers are advancing closer to identifying #CTE in living individuals, potentially revolutionizing treatment options and prevention strategies. By following 1,000 participants with a history of contact sports or military service, BU aims to find biomarkers—traces of CTE in blood or brain scans—that could one day lead to early diagnosis and intervention. This cutting-edge research, combined with AI and machine learning, could make CTE a treatable disease, providing answers to patients and families long before it’s too late. Learn more ⬇️

Highlighting this paper again…. One of the Best Papers from Parkinsonism & Related Disorders Refining the clinical diagnosis of Parkinson's disease https://lnkd.in/gaRNX-r5 IAPRD Secretariat

"Qdata BPH – made possible through our exclusive data partnership with the American Urological Association (AUA) Quality (AQUA)® Registry – provides a granular view of disease progression over time and patient outcomes with key variables curated from unstructured electronic health record data, such as clinician notes. These variables include prostate-specific antigen (PSA) levels, International Prostate Symptom Score (under development), and Gleason scores for those with both BPH and prostate cancer. These variables and other valuable information, such as treatment and procedure details, can provide critical insights into the natural history and management of BPH. “Benign prostatic hyperplasia tends to become more common in men as they get older, affecting 50% of men aged 51 to 60. Treatment options can range from medications to more invasive surgical procedures,” said Sujay Jadhav, CEO of Verana Health. “Our Qdata BPH dataset enables life sciences to make more informed treatment decisions by filling in critical research gaps, ultimately improving patient outcomes and driving meaningful advancements in healthcare.”" #BPH #RWD #EHR

🚀 New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients 🚀 Jvalini Dwarkasing, Chief Scientific Officer at SkylineDx, emphasized the importance of this research: "These findings highlight how the SKY92 test can make a real difference in the care of multiple myeloma patients. By offering a clearer and more reliable way to identify high-risk disease, we are giving doctors powerful tools to tailor treatments and improve outcomes. This research reinforces our commitment to advancing personalized medicine." Click link below for full press release 👇 https://lnkd.in/eB_4FXs6

📢 Just out! This study provides the first Portuguese real-world description of R/M HNSCC patient characteristics, treatment patterns, and supportive care during the year after diagnosis, highlighting population heterogeneity and aiming to improve patient management. Great collab work.

Mouth Cancer Action Month is a campaign that aims to raise awareness of mouth cancer and save lives by promoting the values of prevention and early detection. The campaign is about making everybody more aware and highlighting the risk factors signs and symptoms associated with the disease. By communicating the causes of mouth cancer, the number of people diagnosed with the disease can be reduced, encouraging healthier lifestyles. It is also important to recognize the early warning signs so that a person can act on any unusual changes in the mouth as soon as possible. JCMR is accepting submissions for the upcoming issue! Submit your work via [email protected] Don't miss out on this opportunity to contribute to advancing clinical medicine knowledge! Submit your manuscript today! Image Source: Internet #MouthCancerActionMonth #clinical #medical #research